The TGF-β signaling activated by cancer-associated macrophages promotes cancer stemness and Gefitinib resistance in EGFR-mutant non-small-cell lung cancer.
6 affiliations
- 1Department of Oncology, The First Clinical Medical College, Anhui University of Chinese Medicine, Hefei, China.
- 2Galactophore Oncology Center, Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China.
- 3Department of Oncology, The First Clinical Medical College, Anhui Medical University, Hefei, China.
- 4Department of Oncology, The First Clinical Medical College, Anhui Medical University, Hefei, China. [email protected].
- 5Department of Oncology, The First Clinical Medical College, Anhui University of Chinese Medicine, Hefei, China. [email protected].
- 6Department of Oncology, The Fifth Clinical Medical College, Anhui Medical University, Hefei, China. [email protected].
Abstract
Background
Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains an inevitable challenge in the management of EGFR-mutant non-small cell lung cancer (NSCLC). Although genetic alterations have been extensively characterized, the contribution of tumor microenvironment remodeling and cancer stemness to EGFR-TKIs resistance remains incompletely defined. Here, we investigated the role of transforming growth factor-β (TGF-β) signaling in mediating Gefitinib resistance through tumor-macrophage interactions.Methods
Bioinformatic analyses were performed to identify signaling pathways associated with Gefitinib resistance. Gefitinib-sensitive and resistant NSCLC cell lines were used to evaluate stemness features and drug response by Western blotting, sphere formation, colony formation, and cell viability assays. A macrophage co-culture system was established to assess tumor-associated macrophages (TAMs) polarization and its impact on resistance. Xenograft models were used to validate in vivo effects. The TGF-β inhibitor Disitertide was applied to determine therapeutic potential.Results
TGF-β/SMAD3 signaling was significantly activated in Gefitinib-resistant cells and correlated with poor prognosis. Resistant cells exhibited enhanced stem-like properties, including increased sphere formation and upregulation of stemness-associated markers. TGF-β1 stimulation promoted stemness and reduced Gefitinib sensitivity in sensitive cells, whereas pharmacological inhibition of SMAD3 attenuated these effects and partially restored drug responsiveness. Mechanistically, resistant tumor cells induced macrophage polarization toward a TAMs phenotype via TGF-β1 secretion. TAMs, in turn, reinforced stemness and resistance in tumor cells, establishing a TGF-β-driven positive feedback loop. In vivo, TAMs accelerated tumor growth, while TGF-β inhibition suppressed macrophage polarization and enhanced Gefitinib sensitivity.Conclusion
Our findings demonstrate that TGF-β signaling integrates cancer stemness and macrophage polarization to sustain acquired Gefitinib resistance in EGFR-mutant NSCLC. Targeting the TGF-β axis may represent a promising combinatorial strategy to overcome EGFR-TKIs resistance.
Related
- Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer
- Single-cell RNA Sequencing Analysis Reveals That Targeting PLG–PLGRKT Signaling-mediated Pro-fibrotic Scar-associated Macrophages Ameliorates Liver Fibrosis in Biliary Atresia
- Tumor-associated macrophages beyond M1/M2 in NSCLC: spatially organized programs, therapy resistance, and translational targeting
- Palmitate-activated IRE1-XBP1 signaling limits DNA damage and is associated with H2A.X-linked DNA damage response transcripts in triple-negative breast cancer cells
- Myeloid Lectin Profiling Identifies SYK as a Targetable Signaling Node for Remodeling Immunosuppressive Tumor-Associated Macrophages in Breast Cancer
BibTeX
@article{liu2026tgfβ,
title = {{The TGF-β signaling activated by cancer-associated macrophages promotes cancer stemness and Gefitinib resistance in EGFR-mutant non-small-cell lung cancer.}},
author = {Shihan Liu and Yuanyuan Yu and Sensen Hao and Min Yang and Yiruo Zhang and Junjun Lu and Ke Ruan and Changchun Shao and Yingying Du},
journal = {Stem cell research \& therapy},
year = {2026},
month = aug,
doi = {10.1186/s13287-026-05221-z},
url = {https://europepmc.org/article/MED/42972485},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - The TGF-β signaling activated by cancer-associated macrophages promotes cancer stemness and Gefitinib resistance in EGFR-mutant non-small-cell lung cancer.
AU - Shihan Liu
AU - Yuanyuan Yu
AU - Sensen Hao
AU - Min Yang
AU - Yiruo Zhang
AU - Junjun Lu
AU - Ke Ruan
AU - Changchun Shao
AU - Yingying Du
PY - 2026
DA - 2026/08/04
JO - Stem cell research & therapy
DO - 10.1186/s13287-026-05221-z
UR - https://europepmc.org/article/MED/42972485
AB - Background Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains an inevitable challenge in the management of EGFR-mutant non-small cell lung cancer (NSCLC). Although genetic alterations have been extensively characterized, the contribution of tumor microenvironment remodeling and cancer stemness to EGFR-TKIs resistance remains incompletely defined. Here, we investigated the role of transforming growth factor-β (TGF-β) signaling in mediating Gefitinib resistance through tumor-macrophage interactions.Methods Bioinformatic analyses were performed to identify signaling pathways associated with Gefitinib resistance. Gefitinib-sensitive and resistant NSCLC cell lines were used to evaluate stemness features and drug response by Western blotting, sphere formation, colony formation, and cell viability assays. A macrophage co-culture system was established to assess tumor-associated macrophages (TAMs) polarization and its impact on resistance. Xenograft models were used to validate in vivo effects. The TGF-β inhibitor Disitertide was applied to determine therapeutic potential.Results TGF-β/SMAD3 signaling was significantly activated in Gefitinib-resistant cells and correlated with poor prognosis. Resistant cells exhibited enhanced stem-like properties, including increased sphere formation and upregulation of stemness-associated markers. TGF-β1 stimulation promoted stemness and reduced Gefitinib sensitivity in sensitive cells, whereas pharmacological inhibition of SMAD3 attenuated these effects and partially restored drug responsiveness. Mechanistically, resistant tumor cells induced macrophage polarization toward a TAMs phenotype via TGF-β1 secretion. TAMs, in turn, reinforced stemness and resistance in tumor cells, establishing a TGF-β-driven positive feedback loop. In vivo, TAMs accelerated tumor growth, while TGF-β inhibition suppressed macrophage polarization and enhanced Gefitinib sensitivity.Conclusion Our findings demonstrate that TGF-β signaling integrates cancer stemness and macrophage polarization to sustain acquired Gefitinib resistance in EGFR-mutant NSCLC. Targeting the TGF-β axis may represent a promising combinatorial strategy to overcome EGFR-TKIs resistance.
SN - 1757-6512
ER -